Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3389/fphar.2020.592737 http://scihub22266oqcxt.onion/10.3389/fphar.2020.592737 33708112!7942396!33708112     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Front+Pharmacol 2020 ; 11 (ä): 592737 Nephropedia Template TP {{tp|p=33708112|t=2020. Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2 |pdf=|usr=}}{{33708112}} gab.com Text Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2 JO: Front Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=33708112 #FOAvip Drug repurposing is a rapid approach to identify therapeutics for the treatment of emerging infectious diseases such as COVID-19. To address the urgent need for treatment options, we carried out a quantitative high-throughput screen using a SARS-CoV-2 cytopathic assay with a compound collection of 8,810 approved and investigational drugs, mechanism-based bioactive compounds, and natural products. Three hundred and nineteen compounds with anti-SARS-CoV-2 activities were identified and confirmed, including 91 approved drugs and 49 investigational drugs. The anti-SARS-CoV-2 activities of 230 of these confirmed compounds, of which 38 are approved drugs, have not been previously reported. Chlorprothixene, methotrimeprazine, and piperacetazine were the three most potent FDA-approved drugs with anti-SARS-CoV-2 activities. These three compounds have not been previously reported to have anti-SARS-CoV-2 activities, although their antiviral activities against SARS-CoV and Ebola virus have been reported. These results demonstrate that this comprehensive data set is a useful resource for drug repurposing efforts, including design of new drug combinations for clinical trials for SARS-CoV-2. Twit Text FOAVip Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2 ????Front Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=33708112 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33708112 #FOAvip English Wikipedia <ref>{{Cite pmid|33708112}}</ref> Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2 #MMPMID33708112 Chen CZ; Shinn P; Itkin Z; Eastman RT; Bostwick R; Rasmussen L; Huang R; Shen M; Hu X; Wilson KM; Brooks BM; Guo H; Zhao T; Klump-Thomas C; Simeonov A; Michael SG; Lo DC; Hall MD; Zheng W Front Pharmacol 2020[]; 11 (ä): 592737 PMID33708112show ga Drug repurposing is a rapid approach to identify therapeutics for the treatment of emerging infectious diseases such as COVID-19. To address the urgent need for treatment options, we carried out a quantitative high-throughput screen using a SARS-CoV-2 cytopathic assay with a compound collection of 8,810 approved and investigational drugs, mechanism-based bioactive compounds, and natural products. Three hundred and nineteen compounds with anti-SARS-CoV-2 activities were identified and confirmed, including 91 approved drugs and 49 investigational drugs. The anti-SARS-CoV-2 activities of 230 of these confirmed compounds, of which 38 are approved drugs, have not been previously reported. Chlorprothixene, methotrimeprazine, and piperacetazine were the three most potent FDA-approved drugs with anti-SARS-CoV-2 activities. These three compounds have not been previously reported to have anti-SARS-CoV-2 activities, although their antiviral activities against SARS-CoV and Ebola virus have been reported. These results demonstrate that this comprehensive data set is a useful resource for drug repurposing efforts, including design of new drug combinations for clinical trials for SARS-CoV-2. äDrug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect(epmc).pdf DeepDyve Pubget Overpricing